Literature DB >> 11555602

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

J W Slaton1, T Karashima, P Perrotte, K Inoue, S J Kim, J Izawa, D Kedar, D J McConkey, R Millikan, P Sweeney, C Yoshikawa, T Shuin, C P Dinney.   

Abstract

Tumor invasion and metastasis are regulated by the expression of genes such as E-cadherin, which regulates cell adhesion, and matrix metalloproteinase-9 (MMP-9), which alters the integrity of the extracellular matrix. Both up-regulation of MMP-9 and down-regulation of E-cadherin correlate with bladder cancer metastasis. The purpose of this study was first to determine whether an imbalance between MMP-9 and E-cadherin expression correlates with metastasis from human transitional cell carcinoma (TCC) of the bladder after therapy with neoadjuvant chemotherapy and radical cystectomy and then to determine whether treatment of human TCC xenografts growing in nude mice with interferon (IFN)-alpha would restore this balance, thereby limiting tumor invasion and metastasis. We used in situ hybridization to evaluate the expression of several metastasis-related genes, including MMP-9 and E-cadherin, in paraffin-embedded biopsy specimens from 55 patients with muscle-invasive TCC treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy and radical cystectomy. By multivariate analysis, an MMP-9:E-cadherin ratio of >1.8 was an independent prognostic factor for disease progression. In vitro incubation of an IFN-resistant, highly metastatic human TCC cell line, 253J B-V(R) with noncytostatic concentrations of IFN-alpha down-regulated the activity of MMP-9, up-regulated E-cadherin, and inhibited in vitro invasion. 253J B-V(R) cells were implanted into the bladders of athymic nude mice. Systemic therapy with IFN-alpha (10,000 units s.c. daily) decreased the expression of MMP-9, increased expression of E-cadherin, reduced tumor volume, and inhibited metastasis. The MMP-9:E-cadherin ratio was 4.5 in untreated controls and 1.1 after IFN-alpha treatment. Moreover, systemic low-dose daily IFN-alpha potentiated the efficacy of paclitaxel. These studies indicate that in addition to its antiproliferative and antiangiogenic effects, IFN-alpha limits tumor invasion by restoring the normal balance between MMP-9 and E-cadherin and enhances the activity of systemic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11555602

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  7 in total

Review 1.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

2.  Inhibitory effect of interferon-alpha-2b on expression of cyclooxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice.

Authors:  Bin Cao; Xiao-Ping Chen; Peng Zhu; Lei Ding; Jian Guan; Zuo-Liang Shi
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 3.  Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer.

Authors:  Angélica Ortiz; Serge Y Fuchs
Journal:  Cytokine       Date:  2016-01-25       Impact factor: 3.861

4.  Enhancing the anti-angiogenic action of histone deacetylase inhibitors.

Authors:  Selena Kuljaca; Tao Liu; Andrew E L Tee; Michelle Haber; Murray D Norris; Tanya Dwarte; Glenn M Marshall
Journal:  Mol Cancer       Date:  2007-10-25       Impact factor: 27.401

5.  Type I interferon regulates proteolysis by macrophages to prevent immunopathology following viral infection.

Authors:  Amanda J Lee; Emily Feng; Marianne V Chew; Elizabeth Balint; Sophie M Poznanski; Elizabeth Giles; Ali Zhang; Art Marzok; Spencer D Revill; Fatemeh Vahedi; Anisha Dubey; Ehab Ayaub; Rodrigo Jimenez-Saiz; Joshua J C McGrath; Tyrah M Ritchie; Manel Jordana; Danny D Jonigk; Maximilian Ackermann; Kjetil Ask; Matthew Miller; Carl D Richards; Ali A Ashkar
Journal:  PLoS Pathog       Date:  2022-05-05       Impact factor: 7.464

6.  Diagnostic impact of promoter methylation and E-cadherin gene and protein expression levels in laryngeal carcinoma.

Authors:  Katarzyna Starska; Ewa Forma; Iwona Lewy-Trenda; Paweł Papież; Jan Woś; Magdalena Bryś
Journal:  Contemp Oncol (Pozn)       Date:  2013-06-28

7.  Ephrin-B1 Is a Novel Biomarker of Bladder Cancer Aggressiveness. Studies in Murine Models and in Human Samples.

Authors:  María Victoria Mencucci; Lara Lapyckyj; Marina Rosso; María José Besso; Denise Belgorosky; Mariana Isola; Silvia Vanzulli; Catalina Lodillinsky; Ana María Eiján; Juan Carlos Tejerizo; Matías Ignacio Gonzalez; María Ercilia Zubieta; Mónica Hebe Vazquez-Levin
Journal:  Front Oncol       Date:  2020-03-27       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.